Dirucotide acetate

Key facts

Active substance
Dirucotide acetate
Therapeutic area
Decision number
PIP number
Dirucotide acetate
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Multiple Sclerosis
Route(s) of administration
Intravenous use
Contact for public enquiries
Eli Lilly and Company Limited

E-mail: eu_paediatric@lilly.com
Phone: +44 1276483000

Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)


How useful was this page?

Add your rating